Mandate

Vinge advises Bridgepoint in conjunction with its investment in Vitamin Well

November 29, 2016

Following its formation in 2006, Vitamin Well AB has had the vision of being the best and the tastiest functional drinks manufacturer, adapted for various different target groups and situations. Vitamin Well has its headquarters in Stockholm, employs 84 persons and its drinks are sold in 28 countries. The transaction is conditional upon approval from the Swedish Competition Authority.

Vinge’s team consists of partner Daniel Rosvall together with, among others, associates Samra Baytar and Ilze Lukins (M&A), Tomas Forsgren (intellectual property), Lisa Sennerby (employment), Kristoffer Larson (real estate), Albert Wållgren and Karl Klackenberg (banking & finance) and counsel Johan Cederblad (regulatory issues). Grant McKelvey and Marita Ljunggren are advising on competition law notification issues.

 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026